The routine application of medical device technology to neurological indications beyond pain remains challenging in all but the most severe patients. Micro-cap Neuronetics Inc. is aiming to change all that with its Neurostar transcranial magnetic stimulation (TMS) system that is noninvasive and used in the physician's office.

Word from the FDA to Axsome Therapeutics Inc. about the effort with oral N-methyl-D-aspartate (NMDA) receptor antagonist AXS-05 in depression – and the company's accelerated push with the compound – had Wall Street watching the NMDA space with even more interest than usual.